ATAI | Investor Presentation Deck | 31 slides

The slide uses a vertical timeline-like structure to highlight the 'Huge Need for Development' and a map/metric section for global impact.frame_problem

Open slide detailBeat · Problem

Includes a quote from Keith Nuechterlein and specific Cohen's d effect size metrics.show_traction

Open slide detailBeat · Problem

The slide uses a vertical process flow to demonstrate the progression of clinical validation.present_solution

Open slide detailBeat · Traction

The slide uses a dual-panel layout to compare animal model data (left) with human Phase 1 clinical trial data (right).show_traction

Open slide detailBeat · Traction

The slide highlights that low doses (40 or 80 mg TID) of RL-007 show superior cognitive performance compared to higher doses and Pregabalin.show_traction

Open slide detailBeat · Traction

The slide uses a standard clinical trial flow diagram to illustrate the study protocol.plan_implementation

Open slide detailBeat · Traction

transition

Open slide detailBeat · Traction

The slide uses a split-layout: left side defines the disease and market size, right side outlines the clinical 'urgent need' for innovation.frame_problem

Open slide detailBeat · TractionLoop · Cost Of Inaction

The slide uses a line chart to show MADRS score changes over 12 weeks, highlighting the 25mg dose efficacy.show_traction

Open slide detailBeat · TractionLoop · Cost Of Inaction

The slide uses a timeline-based process diagram to illustrate clinical trial protocols.plan_implementation

Open slide detailBeat · Traction

The slide uses a split layout: a dark sidebar for product specs and a white main area for clinical data visualization.present_solution

Open slide detailBeat · Traction

The slide uses a split-layout with a sidebar for product specs and a main area for study design and results.summarize

Open slide detailBeat · Traction

transition

Open slide detailBeat · Traction

The slide uses a combination of a disease overview, market sizing metrics, and a 'massive unaddressed need' framework to justify the problem.frame_problem

Open slide detailBeat · Traction

The slide uses a split-layout with a left-hand sidebar for product specs and a right-hand main area for clinical evidence and trial design.summarize

Open slide detailBeat · Traction

The slide uses a numbered list to highlight key safety findings alongside a detailed data table.analyze_data

Open slide detailBeat · Traction

The slide uses topographical brain maps to visualize EEG data changes.analyze_data

Open slide detailBeat · Traction

The chart uses error bars and statistical significance markers (asterisks) to compare dose groups against a zero baseline.analyze_data

Open slide detail

The slide uses a checkmark matrix to highlight the competitive advantages of the proposed drug.compare_peers

Open slide detail

transition

Open slide detail

Uses a timeline-style visual to list key statistics about the OUD crisis.frame_problem

Open slide detail

The slide uses a line chart to demonstrate reduction in HCQN subscales over time, and a process diagram to outline the ongoing Phase 1/2 trial stages.show_traction

Open slide detail

The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002 (Ibogaine) against standard MAT and withdrawal support drugs.compare_peers

Open slide detail

inspire_vision

Open slide detail